Skip to main content

Advertisement

Peer Review reports

From: Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study

Original Submission
4 Oct 2012 Submitted Original manuscript
4 Oct 2012 Author responded Author comments - MARIA PIA BRIZZI
Resubmission - Version 2
4 Oct 2012 Submitted Manuscript version 2
9 Dec 2012 Reviewed Reviewer Report - Eileen O'Reilly
23 May 2013 Reviewed Reviewer Report - Bhawna Sirohi
25 May 2013 Reviewed Reviewer Report - Dieter Hörsch
28 Sep 2013 Author responded Author comments - MARIA PIA BRIZZI
Resubmission - Version 3
28 Sep 2013 Submitted Manuscript version 3
28 Sep 2013 Author responded Author comments - MARIA PIA BRIZZI
Resubmission - Version 4
28 Sep 2013 Submitted Manuscript version 4
6 Oct 2013 Reviewed Reviewer Report - Dieter Hörsch
11 Oct 2013 Reviewed Reviewer Report - Bhawna Sirohi
22 Oct 2013 Author responded Author comments - MARIA PIA BRIZZI
Resubmission - Version 5
22 Oct 2013 Submitted Manuscript version 5
Publishing
21 Feb 2014 Editorially accepted
14 Mar 2014 Article published 10.1186/1471-2407-14-184

You can find further information about peer review here.

Back to article page